Biologics Supplier for Orthopedic Practices in Tampa, FL

Vendor qualification for orthopedic practices

Orthopedic practices and ambulatory surgery centers typically qualify a biologics supplier the same way they qualify an implant vendor: by confirming the account is tied to a verified National Provider Identifier, reviewing the documentation that accompanies each lot, and checking that the supplier can reproduce that documentation consistently across orders.

Because Wharton's jelly and exosome products are supplied under an HCT/P framework, many practices ask a supplier to show donor eligibility summaries and third-party sterility testing records before adding a product to a purchasing list, rather than relying on marketing claims.

• NPI number tied to the ordering account
• Certificate of analysis available per lot
• Donor eligibility summary on request
• Lot release record for traceability

Cold-chain receiving for Southeast shipments

Cryopreserved Wharton's jelly products ship overnight on dry ice in validated containers and are intended to move directly into -80 degree C storage on arrival. Practices in the Southeast typically assign one staff member to confirm dry ice level and container integrity at receiving, log the lot number against the shipment, and transfer the product to final storage without delay.

Lyophilized formats, including the freeze-dried Wharton's jelly product and the lyophilized exosome products, are described by the supplier as shelf-stable and do not require this cold-chain step, though the product insert included with each lot should be followed for storage and handling.

Documentation, licensure and the Florida Board of Medicine

Before placing an order, a practice's medical director or compliance lead typically confirms that the ordering physician's license and NPI are current and independently verifies that the intended use fits within the practice's own regulatory analysis. We recommend verifying with the Florida Board of Medicine and the practice's own counsel rather than relying on supplier materials for that determination.

Florida's SB 1768, effective July 1, 2025, addresses physician use of certain non-FDA-approved stem cell therapies in orthopedics, wound care and pain management under informed consent, but it operates at the state level and does not change a product's federal regulatory status. These products are not FDA approved or licensed for any disease or condition; this page is written for licensed healthcare professionals and is not medical or legal advice.

Setting up a Tampa account

Opening an account starts with NPI verification. Once an account is verified, Precision Biologics makes the certificate of analysis, donor eligibility summary and lot release documentation available on request for each order, and offers access to physician-level conversations about that documentation. Pricing is available to verified accounts rather than published, consistent with how documentation-heavy biologics purchasing is typically handled.

FDA has stated there are no FDA-approved exosome products. Exosome products are generally regulated as biologic drugs under section 351 of the Public Health Service Act, not as 361 HCT/Ps. Purchase and clinical use decisions belong to the physician with their own regulatory counsel.

These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.